Huilai Zhang

机构：Harbin Medical University, Tianjin Medical University Cancer Institute and Hospital, Third Affiliated Hospital of Harbin Medical University, Dali University

发表论文 40 篇 · 总被引 260 次 · h-index 7

代表论文

• Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (2025 · Nature Cancer · 被引 52)
• Adverse events in the nervous system associated with blinatumomab: a real-world study (2025 · BMC Medicine · 被引 23)
• Advances in strategies to improve the immunotherapeutic efficacy of chimeric antigen receptor-T cell therapy for lymphoma (2025 · Cancer Biology and Medicine · 被引 4)
• Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2024 · Blood · 被引 4)
• Clinical Risk Stratification and Modifiable Risk Factors for Hepatitis B Virus-Related Follicular Lymphoma (2025 · ImmunoTargets and Therapy · 被引 2)
• Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell of origin and patient outcomes (2025 · Cell Reports Medicine · 被引 2)